Other · 2026
Expert group outlines four recurring problems in psychedelic clinical trials
- Original title
- Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
- Authors
- Lewis BR, Reid MJ, Novick AM, et al.
- Journal
- Journal of psychopharmacology (Oxford, England), 2026
- Molecules
- Psilocybin, LSD, DMT, Mescaline
- Conditions
- Depression, Other
- Evidence grade
- Very low
- Source
- Read the original paper
The question
What practical problems keep coming up when researchers run clinical trials of classical psychedelics, and how might study teams handle them?
What they did
A task group convened by the National Network of Depression Centers, a group of academic depression centres, wrote a position statement on classical psychedelics such as psilocybin, LSD, DMT and mescaline. The authors drew on their own observations from running trials and on the published literature. No new patient data were collected or analyzed.
What they found
The group described four categories of challenges involving trial participants: people who do not respond to treatment; expectancy effects and ‘functional unblinding’, meaning participants can usually tell whether they got the drug or the placebo, which can shape reported results; psychological difficulties that emerge after a dosing session; and ‘contagion effects’, where participants’ experiences and expectations influence one another. For each, the authors suggested management strategies for research teams. They also noted these issues are likely to continue if psychedelic treatments are ever approved for routine psychiatric care.
The fine print
This is a position statement, not a study: there are no participants, no measurements and no statistical results, so the claims reflect expert judgment rather than tested evidence. The recommendations are not validated, and the authors’ own trial experience may not generalize to all settings. This summary is based on the abstract alone, so the specific management strategies proposed are not described here.
What it means
Leading depression researchers are publicly acknowledging that psychedelic trials have design and safety problems that ordinary drug trials do not, including the difficulty of keeping participants unaware of what they received.
Evidence grade: Very low. This is an expert consensus position statement that synthesizes clinical experience and existing literature rather than reporting new data from participants.
This summary is based on the study’s published abstract.